Advertisement

Pharmacy World & Science

, Volume 31, Issue 2, pp 238–240 | Cite as

Two acute psychotic episodes after administration of bupropion: a case of involuntary rechallenge

  • Hervé JavelotEmail author
  • Alexandre Baratta
  • Luisa Weiner
  • Thierry Javelot
  • Cathy Nonnenmacher
  • Jean-Frédéric Westphal
  • Michaël Messaoudi
Case Report

Abstract

Bupropion is an antidepressant drug also used as a smoking cessation aid, which inhibits norepinephrine and dopamine re-uptake. Given its pharmacological properties, it has been associated with reports on psychosis and acute delirious episodes. Case We report the case of a patient with schizoaffective disorder who developed two psychotic episodes respectively after a four and a two-day administration of sustained-release (SR) bupropion at a dose of 150 mg/day. To our knowledge, this is the first reported case of involuntary rechallenge with bupropion SR during a smoking cessation program. Conclusion There is a serious risk of incorrectly identifying bupropion as only a therapy for nicotine withdrawal without taking the precaution of exploring possible psychiatric co-morbidity with addiction. Our case illustrates the problem.

Keywords

Acute psychosis Adverse drug reaction Bupropion Rechallenge Side effects 

Notes

Acknowledgements

The authors want to express their gratitude to the translators, Mr Jean-Yves Bart and Mr Jesse David Tatum, for revising the text.

Conflicts of interest

All the authors of this article attest that there was no potential conflict of interest that could have influenced this work.

References

  1. 1.
    Golden RN, James SP, Sherer MA, Rudorfer MV, Sack DA, Potter WZ. Psychoses associated with bupropion treatment. Am J Psychiatry. 1985;142(12):1459–62.PubMedGoogle Scholar
  2. 2.
    Johnston JA, Lineberry CG, Frieden CS. Prevalence of psychosis, delusions, and hallucinations in clinical trials with bupropion. Am J Psychiatry. 1986;143(9):1192–3.PubMedGoogle Scholar
  3. 3.
    Golden RN. Diethylpropion, bupropion, and psychoses. Br J Psychiatry. 1988;153:265–6. doi: 10.1192/bjp.153.2.265.PubMedCrossRefGoogle Scholar
  4. 4.
    Ames D, Wirshing WC, Szuba MP. Organic mental disorders associated with bupropion in three patients. J Clin Psychiatry. 1992;53(2):53–5.PubMedGoogle Scholar
  5. 5.
    Howard WT, Warnock JK. Bupropion-induced psychosis. Am J Psychiatry. 1999;156(12):2017–8.PubMedGoogle Scholar
  6. 6.
    Neumann M, Livak V, Paul HW, Laux G. Acute psychosis after administration of bupropion hydrochloride (Zyban). Pharmacopsychiatry. 2002;35(6):247–8. doi: 10.1055/s-2002-36393.PubMedCrossRefGoogle Scholar
  7. 7.
    Wang TS, Shiah IS, Yeh CB, Chang CC. Acute psychosis following sustained release bupropion overdose. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(1):149–51. doi: 10.1016/j.pnpbp.2004.10.003.PubMedCrossRefGoogle Scholar
  8. 8.
    Hahn M, Hajek T, Alda M, Gorman JM. Psychosis induced by low-dose bupropion: sensitization of dopaminergic system by past cocaine abuse? J Psychiatr Pract. 2007;13(5):336–8. doi: 10.1097/01.pra.0000290673.32978.e8.PubMedCrossRefGoogle Scholar
  9. 9.
    Dager SR, Heritch AJ. A case of bupropion-associated delirium. J Clin Psychiatry. 1990;51(7):307–8.PubMedGoogle Scholar
  10. 10.
    Liberzon I, Dequardo JR, Silk KR. Bupropion and delirium. Am J Psychiatry. 1990;147(12):1689–90.PubMedGoogle Scholar
  11. 11.
    Van Putten T, Shaffer I. Delirium associated with bupropion. J Clin Psychopharmacol. 1990;10(3):234. doi: 10.1097/00004714-199006000-00028.PubMedCrossRefGoogle Scholar
  12. 12.
    Chan CH, Liu HC, Huang MC. Delirium associated with concomitant use of low-dose bupropion sustained release and fluoxetine. J Clin Psychopharmacol. 2006;26(6):677–9. doi: 10.1097/01.jcp.0000246210.18777.c2.PubMedCrossRefGoogle Scholar
  13. 13.
    Bailey J, Waters S. Acute psychosis after bupropion treatment in a healthy 28-year-old woman. J Am Board Fam Med. 2008;21(3):244–5. doi: 10.3122/jabfm.2008.03.070236.PubMedCrossRefGoogle Scholar
  14. 14.
    Settle EC. Bupropion sustained release: side effect profile. J Clin Psychiatry. 1998;59(Suppl 4):32–6.PubMedGoogle Scholar
  15. 15.
    Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Hervé Javelot
    • 1
    Email author
  • Alexandre Baratta
    • 3
  • Luisa Weiner
    • 4
  • Thierry Javelot
    • 2
  • Cathy Nonnenmacher
    • 1
  • Jean-Frédéric Westphal
    • 4
  • Michaël Messaoudi
    • 5
  1. 1.Secteur PharmacieEtablissement Public Santé Alsace Nord (EPSAN)BrumathFrance
  2. 2.Secteur 38G11Centre Psychothérapique du VionSaint Clair de La TourFrance
  3. 3.Secteur G06Etablissement Public Santé Alsace Nord (EPSAN)67170BrumathFrance
  4. 4.Secteur G03Etablissement Public Santé Alsace Nord (EPSAN)BrumathFrance
  5. 5.Neuropsychopharmacology DepartmentETAP Research CentreVandoeuvre-les-NancyFrance

Personalised recommendations